Expertise in
6
conditions

Dr. Thomas O'brien

Pulmonary Medicine
Pulmonary Disease Specialists - Central Avenue
1121 N Central Ave Ste B, 
Kissimmee, FL 
Expertise in
6
conditions
Pulmonary Disease Specialists - Central Avenue
1121 N Central Ave Ste B, 
Kissimmee, FL 

Overview

Thomas O'brien is a Pulmonary Medicine provider in Kissimmee, Florida. Dr. O'brien is highly rated in 6 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Excessive Daytime Sleepiness.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Critical Care Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Pulmonary Disease Specialists - Central Avenue
1121 N Central Ave Ste B, Kissimmee, FL 34741
Other Locations
Pulmonary Disease Specialists - Cypress Parkway
1012 Cypress Pkwy, Kissimmee, FL 34759

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: September 08, 2022
Intervention Type: Other, Drug
Study Drug: KD025
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 9 Less Clinical Trials
Similar Doctors
Expertise in
22
conditions
Dr. Fortune O. Alabi
Pulmonary Medicine
Expertise in
22
conditions
Dr. Fortune O. Alabi
Pulmonary Medicine

Florida Lung Asthma And Sleep Specialists, P.A.

3480 Polynesian Isle Boulevard, 
Kissimmee, FL 
 (5.8 miles away)
407-507-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fortune Alabi is a Pulmonary Medicine provider in Kissimmee, Florida. Dr. Alabi is highly rated in 22 conditions, according to our data. His top areas of expertise are Asthma, Lung Metastases, Asthma in Children, and Pleural Effusion. Dr. Alabi is currently accepting new patients.

Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine
Expertise in
31
conditions
Dr. Ahmad S. Jalloul
Pulmonary Medicine

Pulmonary Critical Care & Sleep Specialists Of Lake County PA

3121 Citrus Tower Blvd, 
Clermont, FL 
 (24.8 miles away)
352-404-5968
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ahmad Jalloul is a Pulmonary Medicine provider in Clermont, Florida. Dr. Jalloul is highly rated in 31 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Asthma in Children, and Advanced Bronchoscopy. Dr. Jalloul is currently accepting new patients.

Expertise in
38
conditions
Dr. Felipe Ortiz
Pulmonary Medicine
Expertise in
38
conditions
Dr. Felipe Ortiz
Pulmonary Medicine

Lake Pulmonary & Sleep Disorders Clinic P.A.

501 Medical Plaza Dr Ste 102, 
Leesburg, FL 
 (43.3 miles away)
352-728-0709
Languages Spoken:
English
See accepted insurances

Felipe Ortiz is a Pulmonary Medicine provider in Leesburg, Florida. Dr. Ortiz is highly rated in 38 conditions, according to our data. His top areas of expertise are Lung Metastases, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, and Endoscopy.

Frequently Asked Questions about Dr. Thomas O'brien

Is Dr. Thomas O'brien a top-rated expert for Obstructive Sleep Apnea?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas O'brien is classified as an Advanced expert for Obstructive Sleep Apnea, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas O'brien specialize in?

While Dr. Thomas O'brien is a Pulmonary Medicine, they have specific expertise in Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), and Lung Metastases. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Thomas O'brien accept my insurance?

Dr. Thomas O'brien accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'brien's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile